RDx BioScience Genetic Risk Testing Identifies Harmful Mutation in BRCA1 or BRCA2 Human Genes Indicating Higher Likelihood of Breast Cancer

RDx BioScience (RDx) calls for increased use of genetic testing to identify mutations in BRCA1 and BRCA2 , the genes discovered in the 1990s to be strongly associated with a high risk of breast cancer.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, February 5, 2019
Information
Tags: 
Health, Biotechnology, Clinical trials, Medical devices, Oncology, Pharmaceutical, Automotive, FDA, General Automotive, Managed care, Cancer, Breast cancer, Branches of biology, Medicine, Tumor markers, Tumor suppressor genes, RTT, Hereditary cancers, BRCA1, BRCA2, BRCA, Genetic testing
Geotags: 
United States, NEW JERSEY
⚠generated by AI ↴
Summary
Key Points: 
  • RDx BioScience (RDx) calls for increased use of genetic testing to identify mutations in BRCA1 and BRCA2 , the genes discovered in the 1990s to be strongly associated with a high risk of breast cancer.
  • A womans lifetime risk of developing breast and/or ovarian cancer is greatly increased if she inherits a harmful mutation inBRCA1orBRCA2, says Scott Howell,D.O., MPH &TM, CPE,chief medical officer, RDx.
  • Discovering that you have a genetic mutation means you can help prevent breast cancer or find it early, when the chances for successful treatment are highest, says Dr. Howell.
  • Moreover, genetic testing doesnt just affect the individual, since test results also could predict a family members cancer risks.


RDx
BioScience (RDx) calls for increased use of genetic testing to
identify mutations in BRCA1 and BRCA2,
the genes discovered in the 1990s to be strongly associated with a high
risk of breast cancer. RDX, a single source for care quality,
risk evaluation and opioid expertise powered by a fast, full-service
laboratory, raises awareness that these gene mutations are heritable,
can be passed from parent to child, and 70
percent of women with mutations in BRCA1 or BRCA2 will develop breast
cancer before the age of 80.

“A woman’s lifetime
risk of developing breast and/or ovarian cancer is greatly increased
if she inherits a harmful mutation in BRCA1 or BRCA2,”
says Scott Howell, D.O., MPH &TM, CPE, chief medical officer, RDx.
“Genetic risk testing for a true negative result brings a personal sense
of relief, while a positive test result may resolve uncertainties,
allowing people to make informed decisions about their future healthcare
and take steps to reduce cancer risk.”

Only about 5-10
percent of breast cancer is considered to be genetically heritable,
meaning 90-95 percent of women who develop breast cancer do not have an
inherited mutation and may develop cancer for other reasons:
environmental toxin exposure, lifestyle choices and other disease risks.

“Discovering that you have a genetic mutation means you can help prevent
breast cancer or find it early, when the chances for successful
treatment are highest,” says Dr. Howell. “Moreover, genetic testing
doesn’t just affect the individual, since test results also could
predict a family member’s cancer risks. Men and women alike should take
the time to discuss these options with a physician and be ready to do
something about it.”

RDx testing can determine inherited gene mutations that influence breast
cancer, including BRCA1 and BRCA2, as well as TP53, PTEN, STK11, CDH1,
PALB2, CHEK2, ATM, NBN, BARD1 and BRIP1. Additional RDx hereditary risk
testing targets ovarian, uterine, colorectal, and pancreatic cancers.

About RDx

RDx is a full-service, high-technology laboratory. We are fast,
accurate, and deliver value-based service nationally. RDx is accredited
by the College
of American Pathologists (CAP) as a certified, full-service medical
laboratory. Visit www.RDxBioscience.com

Copyright: 
Copyright Business Wire 2019